Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05482282

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

Comparison of Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B at Birth Dose Using New Hepatitis B Bulk (Bio Farma), in Indonesian Infants

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
PT Bio Farma · Industry
Sex
All
Age
1 Day – 3 Days
Healthy volunteers
Accepted

Summary

This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma).

Detailed description

This bridging study is a randomized, double blind, two arms parallel groups, prospective intervention study. Total 220 infants, 0-3 days old will be involved in this study. The subject will be divided into 2 groups, 110 subjects are the investigational group and 110 subjects are the active comparator group. The objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma) and to asses the safety of DTP-HB-Hib Vaccine (Bio Farma) and Recombinant Hepatitis B Vaccine using new Hepatitis B bulk (Bio Farma).

Conditions

Interventions

TypeNameDescription
BIOLOGICALRecombinant Hepatitis B new Bulk vaccine1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma) 1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region.
BIOLOGICALDTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
BIOLOGICALRecombinant Hepatitis B vaccine (Registered BioFarma)1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
BIOLOGICALPentabio3 doses of Pentabio

Timeline

Start date
2025-12-01
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2022-08-01
Last updated
2025-06-05

Locations

3 sites across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT05482282. Inclusion in this directory is not an endorsement.